CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-20 | Venker Eric President & COO | Option exercise 10b5-1 | +100,000 | $3.85 | $385K | 695,580 |
| 2024-12-20 | Venker Eric President & COO | Sale 10b5-1 | −100,000 | $11.49 | $1.1M | 595,580 |
| 2024-12-20 | Venker Eric President & COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 12,226,234 | ||
| 2024-12-20 | Gline Matthew CEO | Shares withheld for taxes | −10,945 | $11.57 | $127K | 17,339,169 |
| 2024-12-18 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise | +412,584 | $3.85 | $1.6M | 19,249,131 |
| 2024-12-18 | Sukhatme Mayukh Pres&Chief Investment Officer | Sale | −412,584 | $12.05 | $5.0M | 18,836,547 |
| 2024-12-18 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise · Stock Option (Right to Buy) | −412,584 | 16,110,600 | ||
| 2024-12-03 | Sukhatme Mayukh Pres&Chief Investment Officer | Other disposition | −3,651,985 | $12.21 | $44.6M | 18,836,547 |
| 2024-11-28 | Pulik Richard CFO | Shares withheld for taxes | −2,341 | $12.69 | $30K | 276,601 |
| 2024-11-20 | Kumar Rakhi Chief Accounting Officer | Shares withheld for taxes | −958 | $11.49 | $11K | 207,408 |
| 2024-11-20 | Venker Eric President & COO | Shares withheld for taxes 10b5-1 | −10,945 | $11.49 | $126K | 606,525 |
| 2024-11-20 | Venker Eric President & COO | Option exercise 10b5-1 | +100,000 | $3.85 | $385K | 706,525 |
| 2024-11-20 | Venker Eric President & COO | Sale 10b5-1 | −100,000 | $11.32 | $1.1M | 606,525 |
| 2024-11-20 | Venker Eric President & COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 12,326,234 | ||
| 2024-11-20 | Gline Matthew CEO | Shares withheld for taxes | −10,945 | $11.49 | $126K | 17,350,114 |
| 2024-10-28 | Pulik Richard CFO | Shares withheld for taxes | −2,341 | $11.84 | $28K | 278,942 |
| 2024-10-21 | MOMTAZEE JAMES C Director | Grant or award | +1,231 | 93,665 | ||
| 2024-10-21 | Epperly Melissa B, Director | Grant or award | +1,613 | 38,037 | ||
| 2024-10-21 | Oren Ilan Director | Grant or award | +2,303 | 97,856 | ||
| 2024-10-21 | Venker Eric President & COO | Option exercise | +100,000 | $3.85 | $385K | 717,470 |
Page 27 of 29 · 570 trades